Suraj Kalia
Stock Analyst at Oppenheimer
(3.89)
# 621
Out of 5,154 analysts
91
Total ratings
48.72%
Success rate
11.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $24.22 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $129.61 | +35.02% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $237.01 | +26.58% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $30.02 | - | 8 | Feb 18, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $140 → $132 | $109.56 | +20.48% | 2 | Jan 23, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $71.35 | +40.15% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $62.99 | +177.82% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $11.53 | +56.11% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $81.64 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $18.14 | +21.28% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $123.59 | -2.90% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $37.04 | -13.61% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $107.39 | -13.40% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.47 | +123.96% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $3.74 | +247.59% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $84.03 | +60.66% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $252.87 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $28.81 | +4.13% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.81 | +24,624.94% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $74.27 | +30.60% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $19.86 | +40.99% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $3.65 | +23.29% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.11 | +1,341.44% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $490.16 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $2.70 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $17.69 | +465.29% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $68.10 | - | 5 | Sep 12, 2018 |
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $24.22
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $129.61
Upside: +35.02%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $237.01
Upside: +26.58%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $30.02
Upside: -
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $140 → $132
Current: $109.56
Upside: +20.48%
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $71.35
Upside: +40.15%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $62.99
Upside: +177.82%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $11.53
Upside: +56.11%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $81.64
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $18.14
Upside: +21.28%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $123.59
Upside: -2.90%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $37.04
Upside: -13.61%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $107.39
Upside: -13.40%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $4.47
Upside: +123.96%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $3.74
Upside: +247.59%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $84.03
Upside: +60.66%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $252.87
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $28.81
Upside: +4.13%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.81
Upside: +24,624.94%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $74.27
Upside: +30.60%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $19.86
Upside: +40.99%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $3.65
Upside: +23.29%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $1.11
Upside: +1,341.44%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $490.16
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $2.70
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $17.69
Upside: +465.29%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $68.10
Upside: -